anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Abiraterone acetate (AA) serves as a medication for managing persistent testosterone production in patients with metastatic castration-resistant prostate cancer (mCRPC). However, its efficacy varies among individuals; thus, the identification of biomarkers to predict and follow treatment response is required. In this pilot study, we explored the potential of circulating microRNAs (c-miRNAs) to stratify patients based on their responsiveness to AA. We conducted an analysis of plasma samples obtained from a cohort of 33 mCRPC patients before and after three, six, and nine months of AA treatment. Using miRNA RT-qPCR panels for candidate discovery and TaqMan RT-qPCR for validation, we identified promising miRNA signatures. Our investigation indicated that a signature based on miR-103a-3p and miR-378a-5p effectively discriminates between non-responder and responder patients, while also following the drug's efficacy over time. Additionally, through in silico analysis, we identified target genes and transcription factors of the two miRNAs, including PTEN and HOXB13, which are known to play roles in AA resistance in mCRPC. In summary, our study highlights two c-miRNAs as potential companion diagnostics of AA in mCRPC patients, offering novel insights for informed decision-making in the treatment of mCRPC.
Ampicillin and sulbactam for injection may be administered by either the IV or the IM routes.

For IV administration, the dose can be given by slow intravenous injection over at least 10-15 minutes or can also be delivered in greater dilutions with 50-100 mL of a compatible diluent as an intravenous infusion over 15-30 minutes.

Ampicillin and sulbactam for injection may be administered by deep intramuscular injection (see DIRECTIONS FOR USE - Preparation for Intramuscular Injection section). The recommended adult dosage of ampicillin and sulbactam for injection is 1.5 g (1 g ampicillin as the sodium salt plus 0.5 g sulbactam as the sodium salt) to 3 g (2 g ampicillin as the sodium salt plus 1 g sulbactam as the sodium salt) every six hours. This 1.5 to 3 g range represents the total of ampicillin content plus the sulbactam content of ampicillin and sulbactam for injection and corresponds to a range of 1 g ampicillin/0.5 g sulbactam to 2 g ampicillin/1 g sulbactam. The total dose of sulbactam should not exceed 4 grams per day.

Pediatric Patients 1 Year of Age or Older

The recommended daily dose of ampicillin and sulbactam for injection in pediatric patients is 300 mg per kg of body weight administered via intravenous infusion in equally divided doses every 6 hours. This 300 mg/kg/day dosage represents the total ampicillin content plus the sulbactam content of ampicillin and sulbactam for injection, and corresponds to 200 mg ampicillin/100 mg sulbactam per kg per day. The safety and efficacy of ampicillin and sulbactam for injection administered via intramuscular injection in pediatric patients have not been established. Pediatric patients weighing 40 kg or more should be dosed according to adult recommendations, and the total dose of sulbactam should not exceed 4 grams per day. The course of intravenous therapy should not routinely exceed 14 days. In clinical trials, most children received a course of oral antimicrobials following initial treatment with intravenous ampicillin and sulbactam for injection (see CLINICAL STUDIES section).
Endoplasmic reticulum (ER)-mitochondria contacts are critical for the regulation of lipid transport, synthesis, and metabolism. However, the molecular mechanism and physiological function of endoplasmic reticulum-mitochondrial contacts remain unclear. Here, we show that Mic19, a key subunit of MICOS (mitochondrial contact site and cristae organizing system) complex, regulates ER-mitochondria contacts by the EMC2-SLC25A46-Mic19 axis. Mic19 liver specific knockout (LKO) leads to the reduction of ER-mitochondrial contacts, mitochondrial lipid metabolism disorder, disorganization of mitochondrial cristae and mitochondrial unfolded protein stress response in mouse hepatocytes, impairing liver mitochondrial fatty acid β-oxidation and lipid metabolism, which may spontaneously trigger nonalcoholic steatohepatitis (NASH) and liver fibrosis in mice. Whereas, the re-expression of Mic19 in Mic19 LKO hepatocytes blocks the development of liver disease in mice. In addition, Mic19 overexpression suppresses MCD-induced fatty liver disease. Thus, our findings uncover the EMC2-SLC25A46-Mic19 axis as a pathway regulating ER-mitochondria contacts, and reveal that impairment of ER-mitochondria contacts may be a mechanism associated with the development of NASH and liver fibrosis.
As a widespread environmental pollutant, microplastics pose a great threat to the tissues and organs of aquatic animals. The carp's muscles are necessary for movement and survival. However, the mechanism of injury of polyethylene microplastics (PE-MPs) to carp muscle remains unclear. Therefore, in this study, PE-MPs with the diameter of 8 μm and the concentration of 1000 ng/L were used to feed carp for 21 days, and polyethylene microplastic treatment groups was established. The results showed that PE-MPs could cause structural abnormalities and disarrangement of muscle fibers, and aggravate oxidative stress in muscles. Exposure to PE-MPs reduced microRNA (miR-21) in muscle tissue, negatively regulated Interleukin-1 Receptor Associated Kinase 4 (IRAK4), activated Nuclear Factor Kappa-B (NF-κB) pathway, induced inflammation, and led to endoplasmic reticulum stress and apoptosis. The present study provides different targets for the prevention of muscle injury induced by polyethylene microplastics.
Participants will attend a screening visit where they will provide a saliva sample for DNA sequencing. Participants will then be separated into two groups based on their gene profile. Group 2 will comprise of participants who possess a second distinct haplotype in the same gene of interest as Group 1. This group will undergo the same study procedures as Haplotype Group 1.
Bone grafts and constructs including stem cells are provided. Example bone grafts include osteogenic stem cells seeded on a scaffold of osteoconductive cortico-cancellous chips and/or osteoinductive demineralized bone. Example constructs include extracellular matrix on a synthetic scaffold, in which the ECM is secreted from MSCs seeded onto the synthetic scaffold. Also provided are methods of making the present bone grafts and scaffolds. Further provided are methods of promoting bone healing and treating wound healing, by administering the present bone grafts and constructs to a mammal in need thereof. Also provided are kits that include the present bone grafts and/or constructs, or components thereof.
This trial was a prospective, multicenter, and self controlled clinical trial. The subjects who were in line with this scheme were detected by fluorimetry and staining, and the primary effectiveness evaluation index, secondary effectiveness evaluation index and safety evaluation index were established during the operation. Record evaluation. At present, in the clinic for sentinel lymph node biopsy of breast cancer, routine medical treatment is a blue staining method. A large number of clinical data show that the number of blue staining methods was 1-2.4, and the number of fluorescence detection is 2-3.7. Therefore, choosing a self controlled clinical trial can increase the number of sentinel lymph node detection.
A method and system of diagnosing a medical condition of a target area of a patient using a mobile device are provided. One or more magnetic field images of a target area of a patient are received. One or more hyperspectral images of the target area of the patient are received. For each of the one or more magnetic field images and the one or more hyperspectral images, a three-dimensional (3D) position of the mobile device is tracked with respect to the target are of the patient. A 3D image of the target area is generated based on the received one or more magnetic field images, one or more hyperspectral images, and the corresponding tracked 3D position of the phone with respect to each image. A medical condition of the target area is diagnosed or monitored based on the generated 3D image.
The invention discloses a drug-loaded nano micelle with multiple drug release functions and a preparation method thereof. Firstly, the beta-CD modified by carboxylation is chemically grafted on a PEG molecular chain to prepare a CD-PEG monomer. Then, the cholesterol derivative is grafted on the molecular chain of the CD-PEG to prepare the Chol-PEG-CD ternary monomer. An ultrasonic emulsification-solvent volatilization method is adopted, and anticancer drugs are encapsulated in the Chol-PEG-CD molecular self-assembly process to prepare the drug-loaded nano micelle. The medicine carrying micelle prepared by the invention has the characteristic of multistage medicine release, wherein the medicine is released suddenly first to realize quick medicine delivery and then is released slowly to realize continuous medicine delivery. The drug-loaded nano micelle can deliver the drug to a focus part in a targeted manner through an EPR effect, and reduces the toxic and side effects of the drug. The drug-loaded nano-micelle with the function of multiple drug release, prepared by the invention, has application advantages in the aspects of targeted delivery of anticancer drugs and tumor treatment.
PURPOSE:To obtain a Japanese and Chinese drug for hair growth effective in generating down and growing hard hair and useful as a remedy for alopecia by using an extraction liquid of a herb mixture as an active component. CONSTITUTION:A liquid extract is prepared by mixing NINJIN (rhizome of Panax ginseng), KOKUTOU (black soy bean), KASHU (root of Polygonum multiflorum), HOKOTSUSHI (bean of Psoralea corylifolia), TOUKI (root of Angelica acutiloba), KEIKETSUTOU (stalk of Mucuna birdwoodiana), SENKYU (rhizome of Cnidium officinale), TANJIN (bark of Schinopsis lorentzii), KOUKA (flower of Carthamus tinctorius), TOUNIN (stone of Prunus persica), BOUFUU (root of Ledebouriella seseloides), SENSOUKON (root of Rubia cordifolia), SOKUHAKUYOU (leaf of Tsuja orientalis), etc. immersing in 75%(V/V) ethanol and leaving standing at a low temperature (5-10 deg.C) for 3 weeks. In the same manner, the above herb mixture is immersed in ethanol and extracted at a high temperature (75 deg.C) for 10hr. The hot extract liquid is mixed to the same amount of the above cold extract liquid and left standing in dark cold place at 5-10 deg.C. The supernatant liquid is used as the objective hair tonic. The remedying effect of herbs having invigorating, blood-refreshing and body-warming effect can be promoted by the addition of KOKUTOU and KASHU having nourishing, tonic and hemopoietic actions, BOUFUU having refreshing action and KEIKETSUTOU having hemopoietic and blood-circulation effect and the side action of the herb can be prevented by the addition of herbs having blood refreshing and hemostatic effect such as SENSOUKON and SOKUHAKUYOU.
When patients are approached in the clinic, they will be given the permission form and asked to participate in the assessment through allowing video-recording and completing the survey. Procedures will be similar to our current operations, with the RSA starting the video-recording equipment before the fellow enters the room and stopping it when the fellow leaves the room. One additional step will be added: When the RSA goes into the room to turn off and remove the video-recording equipment, she will also give the patient the survey, to complete. We expect this survey to take no longer than 5 minutes. In our experience, it is usually at least 10 minutes from when the fellow leaves the room until the attending comes back into the room. Thus, we believe there will be sufficient time for the patient to complete the survey.
Participants will receive an initial in-person consultation with a dietician within 2 weeks of hospital discharge. Then participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person and remote monitoring through a smart phone app and wearable sensor to allow participants to log food intake while sharing their data with a dietician.
This research is a prospective randomized study. Patients will be randomized by number-drawing method. Patients with BMI\>30 and age\>65 will be equally distributed to the experimental and active comparator arms. Under general anesthesia patients will be injected with 5 ml of isosulfan blue into the subareolar region. In one group, breast massage will be applied for 5 minutes. In the other group no massage will be applied. Surgical team will wait for a duration of 5 minutes for the self distribution of the blue dye.
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening condition that has been increasingly recognized in adults and is characterized by a hyperinflammatory state due to immune dysregulation. Its nonspecific presentation, the lack of clinician familiarity given its rarity, and shared clinical features with sepsis and other syndromes can lead to a delay in diagnosis and a poor prognosis. Significant liver function abnormalities as the initial manifestation of HLH are uncommon and can range from mild elevation of aminotransferases to fulminant hepatic failure with high mortality rates. The authors encountered a case of adult HLH mimicking acute viral hepatitis in which a markedly elevated ferritin level led to a prompt diagnosis, early initiation of treatment, and a successful outcome. Clinicians, including gastroenterologists and hepatologists, are often called upon to evaluate patients with abnormal liver tests and may lack experience in the early diagnosis and management of liver dysfunction in the context of HLH. Thus, we expand our reporting to a narrative review of literature which explores the pathogenesis of HLH, challenges associated with its diagnosis, previous reports of liver disease associated with the syndrome, recommended treatments for the familial and adult variations including the role of liver transplantation, and the outcomes of these treatments.
A printing system is disclosed where a multi level pixel image ( 200 ) is converted into a half tone image ( 300 ) utilising a set of bit mask arrays ( 350 - 0  to  350 - 255 ) stored within a memory ( 310 ). The value of a multi level pixel is used to select one of the stored bit mask arrays. The co-ordinates of the multi level pixel in an image are then used to identify an entry from within the selected bit mask array. The identified entry is then used to set the value of the corresponding pixel in the half tone image. In order to reduce the appearance of contouring at the boundaries of adjacent portions of an image having similar grey levels, the stored bit mask arrays ( 350 - 0  to  350 - 255 ) are such that the majority of entries in the bit mask arrays for successive grey levels are identical. In addition to reducing contouring problems, the similarity of significant portions of bit mask arrays for successive grey levels make the bit mask arrays suitable for compression.
FIELD: veterinary medicine. SUBSTANCE: method deals with improving the immune status of iron deficiency anemia in farm animals. For this purpose, animal is given a preparation of complex compounds of zinc and iron and unrefined caned sugar at 0.5-4 ml/kg body weight. For the treatment, 1-mo-aged calves and piglets are given the preparation once daily for 10-15 d up to normalization of hemoglobin level. The method enables to normalize the immune status due to metabolic restoration and decrease the expenses for animals' treatment. EFFECT: higher efficiency. 1 cl, 2 tbl
The safety and effectiveness of LYUMJEV to improve glycemic control in pediatric patients with diabetes mellitus have been established. Use of LYUMJEV for this indication is supported by evidence from an adequate and well-controlled study in 716 pediatric patients with type 1 diabetes mellitus aged 1 year and older, and from studies in adult and pediatric patients with diabetes mellitus [see Clinical Pharmacology (12.3) and Clinical Studies (14.5)]. 

LYUMJEV-treated pediatric patients reported a higher incidence of subcutaneous injection site-related reactions compared to LYUMJEV-treated adults [see Adverse Reactions (6.1)]. It is expected that LYUMJEV-treated pediatric patients who receive continuous subcutaneous insulin infusion (CSII) are more likely to have infusion site-related adverse reactions than those who receive subcutaneous injections [see Adverse Reactions (6.1)]. Monitor injection and infusion sites closely when initiating therapy with LYUMJEV in pediatric patients. If persistent injection or infusion site reactions occur, discontinue LYUMJEV and initiate therapy with an alternative insulin.
Multiple myeloma (MM) is a hematological malignancy whose curability is greatly challenged by recurrent patient relapses and therapy resistance. We have previously proposed the high expression of ADAM8, ADAM9 and ADAM15 (A Disintegrin And Metalloproteinase 8/9/15) as adverse prognostic markers in MM. This study focused on the so far scarcely researched role of ADAM8/9/15 in MM using two patient cohorts and seven human MM cell lines (HMCL). High ADAM8/9/15 expression was associated with high-risk cytogenetic abnormalities and extramedullary disease. Furthermore, ADAM8/15 expression increased with MM progression and in relapsed/refractory MM compared to untreated patient samples. RNA sequencing and gene set enrichment analysis comparing ADAM8/9/15high/low patient samples revealed an upregulation of proliferation markers and proliferation-associated gene sets in ADAM8/9/15high patient samples. High ADAM8/9/15 expression correlated with high Ki67 and high ADAM8/15 expression with high MYC protein expression in immunohistochemical stainings of patient tissue. Conversely, siRNA-mediated knockdown of ADAM8/9/15 in HMCL downregulated proliferation-related gene sets. Western blotting revealed that ADAM8 knockdown regulated IGF1R/AKT signaling and ADAM9 knockdown decreased mTOR activation. Lastly, high ADAM8/9/15 expression levels were verified as prognostic markers independent of Ki67/MYC expression and/or high-risk abnormalities. Overall, these findings suggest that ADAM8/9/15 play a role in MM progression and proliferation signaling.
Inherited cardiovascular diseases are rare diseases that are difficult to diagnose by non-expert professionals. Genetic analyses play a key role in the diagnosis of these diseases, in which the identification of a pathogenic genetic variant is often a diagnostic criterion. Therefore, genetic variant classification and routine reinterpretation as data become available represent one of the main challenges associated with genetic analyses. Using the genetic variants identified in an inherited cardiovascular diseases unit during a 10-year period, the objectives of this study were: 1) to evaluate the impact of genetic variant reinterpretation, 2) to compare the reclassification rates between different cohorts of cardiac channelopathies and cardiomyopathies, and 3) to establish the most appropriate periodicity for genetic variant reinterpretation. All the evaluated cohorts (full cohort of inherited cardiovascular diseases, cardiomyopathies, cardiac channelopathies, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic cardiomyopathy, Brugada syndrome, long QT syndrome and catecholaminergic polymorphic ventricular tachycardia) showed reclassification rates above 25%, showing even higher reclassification rates when there is definitive evidence of the association between the gene and the disease in the cardiac channelopathies. Evaluation of genetic variant reclassification rates based on the year of the initial classification showed that the most appropriate frequency for the reinterpretation would be 2 years, with the possibility of a more frequent reinterpretation if deemed convenient. To keep genetic variant classifications up to date, genetic counsellors play a critical role in the reinterpretation process, providing clinical evidence that genetic diagnostic laboratories often do not have at their disposal and communicating changes in classification and the potential implications of these reclassifications to patients and relatives.
Serious and rarely fatal anaphylactic reactions have been reported in patients receiving therapy with QDOLO. When these events do occur, it is often following the first dose. Other reported allergic reactions include pruritus, hives, bronchospasm, angioedema, toxic epidermal necrolysis and Stevens-Johnson syndrome. Patients with a history of hypersensitivity reactions to tramadol and other opioids may be at increased risk and therefore should not receive QDOLO [see Contraindications ( 4)] . If anaphylaxis or other hypersensitivity occurs, stop administration of QDOLO immediately, discontinue QDOLO permanently, and do not rechallenge with any formulation of tramadol. Advise patients to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction. [see Contraindications ( 4)] .
PURPOSE:To obtain clear juice of citrus fruit peel for cosmetic use without losing the active components of the peel such as vitamins, amino acids, etc., by removing pulp from the waste slurry containing the fruit peel and in some cases the essential oil and produced as a by-product in the production of citrus fruit juice, treating the refined slurry with a pectinase, and filtering the product. CONSTITUTION:Citrus fruits are squeezed with an inline-type whole-fruit juicer to obtain the fruit juice for drink. The waste slurry or waste emulsion obtained as the residue and containing the citrus peel or citrus peel and essential oil is treated preferably with an automatic discharging 3-layer-separating ultracentrifugal separator to separate the pulp and excess essential oil. The obtained slurry is added with 0.005-1%, preferably 0.01-0.4% pectinase, and made to react at 20-60 deg.C, preferably 40-50 deg.C for 4-16hr. After the completion of the reaction, the product is filtered to obtain clear juice of citrus fruit peel. The juice is expected to be useful as a cosmetic having emollient, astringent or protective effect to the skin.
The present invention provides a method for reasonable and sensitive life support services. Meters in a customer house  1  are continuously connected to a common meter-reading center  2  by an automatic meter-reading system provided by a lifeline provider. The common meter-reading center  2  is made to have an intermediary device  2  which detects an abnormality from meter-reading results and notifies a support company, thus intermediating between the customer  1  and the support company  3 . Since the intermediary device  2  is continuously connected to the meters, the meter-reading results can be frequently (e.g. once an hour) collected and analyzed. Therefore time lag between occurrence of an abnormality and detection of the abnormality can be reduced and delays in response can be prevented. By sending a list of treatments to be done from the intermediary device  2  to a PC in the customer house  1  or portable terminals of support members sent to a scene, appropriate treatments can be performed by non-professionals.